Could the menagerie of the gut microbiome really cure cancer? Hope or hype
Abstract The investigational scale of the gut microbiome is expanding rapidly. In 2018, the intersection of gut microbiota and immuno-oncology received much attention. While the impact of gut microbiota on the immune system was already established, the year received an exponential expansion of micro...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0561-9 |
id |
doaj-e3dfec5409764267ab74afbfb6dc69b6 |
---|---|
record_format |
Article |
spelling |
doaj-e3dfec5409764267ab74afbfb6dc69b62020-11-25T03:03:55ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262019-04-01711710.1186/s40425-019-0561-9Could the menagerie of the gut microbiome really cure cancer? Hope or hypeMuhammad Bilal Abid0Division of Hematology/Oncology, Department of Medicine, Medical College of WisconsinAbstract The investigational scale of the gut microbiome is expanding rapidly. In 2018, the intersection of gut microbiota and immuno-oncology received much attention. While the impact of gut microbiota on the immune system was already established, the year received an exponential expansion of microbiome’s role in the immunotherapy setting. The microbiome research pipeline is ripe for large-scale, prospective trials. Working knowledge of immune-based cancer treatments, heterogeneity in their responses and resistance mechanisms, relevant immunological and microbiological pathways and potential for gut microbiome in enhancing the responses, is critical.http://link.springer.com/article/10.1186/s40425-019-0561-9ImmunotherapyAdoptive cellular therapyChimeric antigen receptor (CAR) T-cellsGut microbiomeDysbiosisCRISPR/cas9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Muhammad Bilal Abid |
spellingShingle |
Muhammad Bilal Abid Could the menagerie of the gut microbiome really cure cancer? Hope or hype Journal for ImmunoTherapy of Cancer Immunotherapy Adoptive cellular therapy Chimeric antigen receptor (CAR) T-cells Gut microbiome Dysbiosis CRISPR/cas9 |
author_facet |
Muhammad Bilal Abid |
author_sort |
Muhammad Bilal Abid |
title |
Could the menagerie of the gut microbiome really cure cancer? Hope or hype |
title_short |
Could the menagerie of the gut microbiome really cure cancer? Hope or hype |
title_full |
Could the menagerie of the gut microbiome really cure cancer? Hope or hype |
title_fullStr |
Could the menagerie of the gut microbiome really cure cancer? Hope or hype |
title_full_unstemmed |
Could the menagerie of the gut microbiome really cure cancer? Hope or hype |
title_sort |
could the menagerie of the gut microbiome really cure cancer? hope or hype |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2019-04-01 |
description |
Abstract The investigational scale of the gut microbiome is expanding rapidly. In 2018, the intersection of gut microbiota and immuno-oncology received much attention. While the impact of gut microbiota on the immune system was already established, the year received an exponential expansion of microbiome’s role in the immunotherapy setting. The microbiome research pipeline is ripe for large-scale, prospective trials. Working knowledge of immune-based cancer treatments, heterogeneity in their responses and resistance mechanisms, relevant immunological and microbiological pathways and potential for gut microbiome in enhancing the responses, is critical. |
topic |
Immunotherapy Adoptive cellular therapy Chimeric antigen receptor (CAR) T-cells Gut microbiome Dysbiosis CRISPR/cas9 |
url |
http://link.springer.com/article/10.1186/s40425-019-0561-9 |
work_keys_str_mv |
AT muhammadbilalabid couldthemenagerieofthegutmicrobiomereallycurecancerhopeorhype |
_version_ |
1724683833103613952 |